Uncategorized Archives - Page 30 of 134

WednesdayDec 28, 2022 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trials The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3% The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed to evaluate the ability of ADI(TM) to restore immune tolerance Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping…

WednesdayDec 28, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers CNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM treatment to market The company aims to enroll more than 200 patients in its global Berubicin trial on a 2:1 randomization schema comparing Berubicin-treated patients to those receiving second-line standard of care chemotherapy agent lomustine…

TuesdayDec 27, 2022 10:30 am

Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up listing on a national exchange The company’s products include its flagship patented shoe insole device enabled with GPS, Bluetooth, and Wi-Fi functionality for tracking seniors or people with autism prone to wandering and getting lost,…

ThursdayDec 22, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system The company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain barrier, in a potentially pivotal Phase 2 trial involving patients with recurrent glioblastoma multiforme (“GBM”) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event in which he provided an update on recent key events and plans for the future in addition to allaying the investors’ concerns regarding the recent reverse stock split CNS Pharmaceuticals…

WednesdayDec 21, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”) The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient This key data enables physicians to assess whether symptoms may be the result of a heart attack HeartBeam’s (NASDAQ: BEAT) small, portable, easy-to-use heart-attack detection solution was the focus of a recent Big Biz Show episode; the Big Biz Show features fast-talking, hard-hitting discussions on business and finance. During the interview, Big Biz Show host Bob “Sully” Sullivan chatted with HeartBeam founder and CEO Branislav…

TuesdayDec 20, 2022 11:15 am

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

Jupiter Wellness has announced that the “FDA of India” has approved its topical treatment for psoriasis and vitiligo, with a market launch to follow The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026 JW-500, a topical treatment for female sexual wellness, is currently in development with plans to file for pre-IND and Orphan Drug Designation within the next year Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”)…

MondayDec 19, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection

BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch Projections for global smartwatch and wearables medical-device markets show consistent upward growth In a world where an estimated 202.6 million people use smartwatches (https://ibn.fm/zb66P), the ability to harness the power of smartwatches to help people live healthier lives can make a profound difference. That’s exactly what HeartBeam (NASDAQ: BEAT), a cardiac technology company with a track record for innovation and cutting-edge technology, hopes to do with…

FridayDec 16, 2022 12:00 pm

Jupiter Wellness Inc. (NASDAQ: JUPW) Is ‘One to Watch’

Jupiter Wellness’s product pipeline addresses a range of underserved conditions, including hair loss, eczema, burns, and sexual wellness The company’s revenue is generated through OTC and consumer product sales, contract research agreements, and licensing royalties Jupiter Wellness recently announced that it has been approved to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs Jupiter Wellness (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary…

FridayDec 16, 2022 11:15 am

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

Ludlow Research ups price target for MetAlert, leading developer of location-sensitive health monitoring devices and wearable technology products, anticipating target between $1 and $1.25 per share MetAlert announced the elimination of all its toxic convertible notes from its balance sheet, which now provides increased stability to its public float The company also shared improved guidance to its NFC operations while also announcing the launch of new medical devices geared toward the geriatric and autism healthcare markets Q4 2022 also saw the influx of new chips, which will significantly increase production of the company’s SmartSole units in early 2023, ramp up…

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

Advisory Firm Appointment Underscores MetAlert, Inc. (MLRT) Strategy Amid Growth Stage and New Patient Location-tracking Technology Rollout

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection

Jupiter Wellness Inc. (NASDAQ: JUPW) Is ‘One to Watch’

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search